Royal Bank Of Canada Upgrades CSL (OTCMKTS:CSLLY) to “Moderate Buy”

CSL (OTCMKTS:CSLLY) was upgraded by stock analysts at Royal Bank Of Canada from a “hold” rating to a “moderate buy” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other brokerages have also recently weighed in on CSLLY. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CSL has a consensus rating of “Hold”.

CSL Stock Down 3.2%

Shares of OTCMKTS CSLLY opened at $30.65 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The firm has a fifty day moving average of $25.97 and a 200-day moving average of $23.34. CSL has a 52-week low of $16.01 and a 52-week high of $36.28.

CSL Company Profile

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.